https://www.statnews.com/2020/04/27/arthritis-drug-kevzara-disappoints-as-coronavirus-treatment/
Bad news for IL6 inhibitor Kevaza (trial stopped for futility, only slight signal of efficacy is in very severes).
"CNBC noted that Regeneron and Sanofi announced on Monday that their rheumatoid arthritis drug, Kevzara, showed promise for treating the sickest coronavirus patients in a clinical trial but was not beneficial for patients with less-advanced disease. The companies said they would stop testing the drug in that group, which featured patients characterized as "severe," those requiring low levels of supplemental oxygen and who were not on ventilators. Sicker patients characterized as "critical," those requiring mechanical ventilation, high-flow oxygen or treatment in intensive care, did show a benefit from Kevzara compared with a placebo. The companies are proceeding with a larger trial of this group and results are expected by June." The benefit for the sickest pts was modest, about 10% benefited.
This is pretty disappointing, after
https://www.aphp.fr/contenu/le-tocilizumab-ameliore-significativement-le-pronostic-des-patients-avec-pneumonie-covid
which was apparently good news for IL6 inhibitor Actemra (although this is a smaller and open label trial, and no details were given).